The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
dc.contributor.author | Vishwanathan, K | |
dc.contributor.author | Dickinson, P | |
dc.contributor.author | So, K | |
dc.contributor.author | Thomas, K | |
dc.contributor.author | Chen, Y | |
dc.contributor.author | de Castro Carpeno, J | |
dc.contributor.author | Dingemans, A | |
dc.contributor.author | Kim, H | |
dc.contributor.author | Kim, J | |
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Yang, J | |
dc.contributor.author | Bui, K | |
dc.contributor.author | Weilert, D | |
dc.contributor.author | Harvey, R | |
dc.date.accessioned | 2018-03-17T21:24:17Z | |
dc.date.available | 2018-03-17T21:24:17Z | |
dc.date.issued | 2018-01-30 | |
dc.identifier.citation | The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. 2018, Br J Clin Pharmacol | en |
dc.identifier.issn | 1365-2125 | |
dc.identifier.pmid | 29381826 | |
dc.identifier.doi | 10.1111/bcp.13534 | |
dc.identifier.uri | http://hdl.handle.net/10541/620849 | |
dc.description.abstract | We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to British journal of clinical pharmacology | en |
dc.title | The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. | en |
dc.type | Article | en |
dc.contributor.department | Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA, USA | en |
dc.identifier.journal | British Journal of Clinical Pharmacology | en |
html.description.abstract | We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported. |